FY2025 EPS Estimate for Anixa Biosciences Boosted by Analyst

Anixa Biosciences, Inc. (NASDAQ:ANIX - Free Report) - Research analysts at HC Wainwright raised their FY2025 EPS estimates for shares of Anixa Biosciences in a note issued to investors on Tuesday, June 3rd. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings per share of ($0.38) for the year, up from their prior forecast of ($0.41). HC Wainwright currently has a "Buy" rating and a $7.00 price objective on the stock. The consensus estimate for Anixa Biosciences' current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Anixa Biosciences' FY2026 earnings at ($0.39) EPS.

Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last announced its quarterly earnings data on Tuesday, June 3rd. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.01.

A number of other equities analysts also recently commented on ANIX. D. Boral Capital restated a "buy" rating and issued a $10.00 price objective on shares of Anixa Biosciences in a report on Thursday, May 29th. Maxim Group started coverage on shares of Anixa Biosciences in a research report on Friday, March 21st. They issued a "buy" rating and a $10.00 target price for the company.

Anixa Biosciences Trading Down 2.8%

ANIX stock traded down $0.08 during mid-day trading on Thursday, hitting $2.76. The stock had a trading volume of 80,922 shares, compared to its average volume of 90,442. Anixa Biosciences has a 1-year low of $2.07 and a 1-year high of $4.20. The company has a fifty day moving average of $2.66 and a 200 day moving average of $2.80. The stock has a market capitalization of $88.90 million, a price-to-earnings ratio of -7.08 and a beta of 0.34.

Institutional Trading of Anixa Biosciences

Several large investors have recently modified their holdings of ANIX. Focus Partners Wealth bought a new position in Anixa Biosciences in the 4th quarter worth $162,000. LPL Financial LLC increased its stake in shares of Anixa Biosciences by 37.2% in the fourth quarter. LPL Financial LLC now owns 42,937 shares of the company's stock worth $100,000 after purchasing an additional 11,633 shares during the period. Jane Street Group LLC acquired a new position in shares of Anixa Biosciences during the 4th quarter worth about $67,000. Prosperity Wealth Management Inc. acquired a new position in shares of Anixa Biosciences during the 4th quarter worth about $54,000. Finally, Renaissance Technologies LLC boosted its stake in Anixa Biosciences by 36.5% during the 4th quarter. Renaissance Technologies LLC now owns 14,573 shares of the company's stock valued at $34,000 after purchasing an additional 3,900 shares during the period. 29.13% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, CEO Amit Kumar purchased 10,000 shares of the company's stock in a transaction dated Wednesday, June 4th. The shares were bought at an average price of $2.85 per share, with a total value of $28,500.00. Following the completion of the transaction, the chief executive officer now directly owns 569,925 shares in the company, valued at $1,624,286.25. This trade represents a 1.79% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 25.30% of the company's stock.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.